NYSE:PLX
Protalix BioTherapeutics, Inc.
A clinical-stage biopharmaceutical firm developing novel antibody-drug conjugates for solid tumor oncology with current annual revenues near $53M.
Key Metrics
Investment Thesis
Bull Case
Protalix offers exposure to a novel ADC platform with differentiated technology that could capture significant market share in the competitive solid tumor oncology space if key clinical trials succeed, supported by a recent return to profitability and positive operating cash flow. The company's asset-light balance sheet relative to its R&D focus allows for strategic flexibility while maintaining a manageable current ratio of approximately 2.3x.
Bear Case
Investors should be cautious regarding the deep accumulated deficit of $378.4M and the recent decline in revenue from 2023, which may indicate commercial headwinds or delayed market penetration for key products. The substantial cash burn and reliance on financing activities pose liquidity risks if future fundraising markets tighten or if clinical milestones are not met as projected.
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) primarily for oncology markets. The company generates revenue through the commercialization of its lead asset, PTX-100, which targets solid tumors and leverages proprietary linker technology to enhance therapeutic efficacy. With total assets of $73.4M and recent revenue of $53.4M, the firm is navigating a critical phase between clinical development milestones and early-stage commercial scaling.
Analysis
Management Discussion
The company reported revenue of $53.4M in 2024, representing a notable contraction from 2023's $65.5M, while maintaining profitability with net income of $2.9M despite elevated operating expenses of $25.2M. Cash flow from operations turned positive at $8.7M, providing some liquidity buffer, though the significant cash outflow from financing activities of $16.8M suggests ongoing capital needs for development or strategic transactions.
Industry Overview
The global oncology drug market is highly competitive with rapid innovation in antibody-drug conjugates, where differentiation through proprietary linkers and payload delivery systems is becoming a critical success factor. Companies in this sector face intense pressure to demonstrate superior efficacy and safety profiles against existing standards of care while managing high R&D costs and regulatory hurdles.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $47.6M | $65.5M | $53.4M |
| Cost of Revenue | $19.6M | $23.0M | $24.3M |
| Gross Profit | $28.0M | $42.5M | $29.1M |
| Operating Expenses | $41.1M | $32.1M | $25.2M |
| Operating Income | $-13.0M | $10.5M | $3.9M |
| R&D | $29.3M | $17.1M | $13.0M |
| G&A | $11.7M | $15.0M | $12.2M |
| Stock-Based Comp | $2.1M | $3.4M | $3.3M |
| Depreciation | $1.1M | $1.2M | $1.3M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-1.4M | $-1.9M | $237.0K |
| Pre-Tax Income | $-14.4M | $8.6M | $4.2M |
| Income Tax | $530.0K | $254.0K | $1.2M |
| Continuing Ops | $-14.9M | $8.3M | $2.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-14.9M | $8.3M | $2.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-14.9M | $8.3M | $2.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $44.9M | $69.9M | $60.1M |
| Cash & Equivalents | $17.1M | $23.6M | $19.8M |
| Accounts Receivable | $4.6M | $5.3M | $2.9M |
| Inventory | $16.8M | $19.0M | $21.2M |
| Other Current Assets | $6.4M | $22.0M | $16.2M |
| Long-Term Assets | $10.9M | $14.5M | $13.3M |
| PP&E (Net) | $4.6M | $5.0M | $4.6M |
| Operating Leases | $5.1M | $5.9M | $5.4M |
| Other LT Assets | $1.3M | $3.6M | $3.3M |
| Total Assets | $55.8M | $84.4M | $73.4M |
| Current Liabilities | $32.4M | $45.5M | $25.6M |
| Accounts Payable | $12.3M | $19.6M | — |
| Current Leases | $1.1M | $1.4M | $1.5M |
| Deferred Revenue | $13.2M | $0 | — |
| Other Current Liab | $-2.1M | $15.6M | $14.6M |
| Long-Term Liabilities | $34.0M | $5.3M | $4.6M |
| LT Operating Leases | $4.2M | $4.6M | $4.0M |
| Other LT Liab | $29.8M | $714.0K | $559.0K |
| Total Liabilities | $66.4M | $50.9M | $30.2M |
| Shareholders' Equity | $-10.6M | $33.6M | $43.2M |
| Retained Earnings | $-389.9M | $-381.5M | $-378.4M |
| Total L&E | $55.8M | $84.4M | $73.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-14.9M | $8.3M | $2.9M |
| Non-Cash Adjustments | $1.8M | $-4.4M | $5.2M |
| Working Capital Changes | $-11.9M | $-5.2M | $577.0K |
| Cash from Operations | $-25.0M | $-1.3M | $8.7M |
| Capital Expenditures | $628.0K | $1.1M | $1.3M |
| Cash from Investing | $-5.0M | $-16.7M | $4.2M |
| Cash from Financing | $8.2M | $24.7M | $-16.8M |
| FX Effect | $-77.0K | $-114.0K | $25.0K |
| Net Change in Cash | $-21.9M | $6.5M | $-3.9M |
| Beginning Cash | $39.0M | $17.1M | $23.6M |
| Ending Cash | $17.1M | $23.6M | $19.8M |
Frequently Asked Questions
How does Protalix BioTherapeutics, Inc. make money?
Oncology Therapeutics (ADC platforms including PTX-100 for solid tumors), Commercial Revenue Streams (sales from approved indications and partnerships), and Research & Development (clinical trials and proprietary linker technology development).
What are the main risks for PLX?
Significant reliance on the single lead asset PTX-100 with substantial commercialization risk if patient enrollment or approval timelines slip, heavy dependence on external funding given the retained earnings deficit of $378.4M, and potential volatility in oncology drug pricing and reimbursement landscapes.
What is PLX's competitive advantage?
Proprietary antibody-drug conjugate platform featuring unique cleavable linkers designed to reduce off-target toxicity, established commercial relationships with key oncology partners, and a streamlined pipeline focused on high-need solid tumor indications.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.